Ervatamia divaricata extract, preparation method thereof and application of ervatamia divaricata extract in resisting brain metastatic tumor

By extracting the monoterpenoid indole alkaloid compound GYH90MT from *Cynodon dactylon*, the problem of existing drugs being unable to cross the blood-brain barrier has been solved, enabling effective treatment of brain metastases from breast cancer.

CN121378211APending Publication Date: 2026-01-23CHINESE MEDICINE GUANGDONG LABORATORY +1
0 Cites 2 Cited by

Patent Information

Application Number
CN202511653866.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-11-11
Publication Date
2026-01-23

AI Technical Summary

Technical Problem

Existing drugs for treating brain metastases have difficulty crossing the blood-brain barrier to achieve effective concentrations, resulting in unsatisfactory treatment outcomes, especially for brain metastases from lung and breast cancer.

Method used

The extract GYH90MT from *Cynodon dactylon* was used to isolate monoterpenoid indole alkaloids, including ervaflabelline A, ervaflabelline B, and ervaflabelline C, through reflux extraction, column chromatography, and gradient elution. These compounds were then used to prepare drugs for treating brain metastases.

Benefits of technology

GYH90MT exhibits significant cytotoxic inhibitory activity, effectively inhibiting the growth of 4T1 brain metastases from breast cancer, with no obvious adverse reactions in mice, and its effects are time- and dose-dependent.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention provides an ervatamia divaricata extract as well as a preparation method and application of the ervatamia divaricata extract in resisting brain metastatic tumor. Pharmacological activity shows that the extract of ervatamia divaricata disclosed by the invention has remarkable cytotoxicity inhibition activity, and the inhibition effect of the extract is time-dependent and dose-dependent. The extract can inhibit the growth of breast cancer 4T1 brain metastases, and has no obvious adverse reaction on mice.
Need to check novelty before this filing date? Find Prior Art